The effect was consistent when tested using a second siRNA sequence against FABP4 (Supplementary Fig. 1e and f), as well as another ovarian cancer cell line (Ovcar 5; Supplementary Fig. 1g and h). This evidence concerns the gene FABP4 and ovarian cancer.